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Abstract
Background: This article highlights the experiences of a unique group. In January 2011, Dave Murray organized a
group of participants from the North American Opiate Medication Initiative (NAOMI) heroin-assisted treatment
clinical trials from 2005 to 2008 in the Downtown Eastside of Vancouver (DTES), B.C., Canada. The NAOMI Patients
Association (NPA) is an independent group that currently meets every Saturday in the DTES. Currently, all members
of the NPA are former participants in the heroin stream of the clinical trial. The NPA offers support, education, and
advocacy to its members.
Methods: Drawing on brainstorming sessions and focus groups that were conducted in the summer of 2011, this
paper highlights the experiences of NPA members in their own words.
Results: The findings provide a lens to understand how becoming a research subject for the NAOMI trial impacted
the lives of NPA members, both positive and negative. The NPA members discuss ethics, consent, recommendations
for future HAT programs and studies, and ongoing advocacy.
The NAOMI Patients Association (NPA):
participant support and advocacy
In January 2011, Dave Murray organized a group of par-
ticipants from the North American Opiate Medication
Initiative (NAOMI) heroin-assisted treatment clinical
trial from 2005 to 2008 in the Downtown Eastside of
Vancouver (DTES), B.C., Canada. The NAOMI Patients
Association (NPA) is an independent group that cur-
rently meets every Saturday at Vancouver Area Network
of Drug Users (VANDU). The NPA is associated with
the British Columbia Association of People On Metha-
done (BCAPOM). From its inception to early 2012, all
members of the NPA were former participants in the
heroin stream of the NAOMI clinical trial. Many former
NAOMI participants had a difficult time following the
cessation of the NAOMI study. Dave Murray recognized
this and as a result initiated the formation of the NPA,
in January of 2011. The NPA began to meet weekly at
VANDU to offer support, education, and advocacy for
its members. The NPA has reached out to all former
NAOMI participants in the heroin stream of the clinical
trial. Although attendance at weekly meetings varies, the
highest attendance at a meeting was 44 members. On aver-
age, 15 members gather each week. Currently, a number of
NPA members are also research subjects in another
clinical trial in Vancouver: Study to Assess Longer-
term Opiate Medication Effectiveness (SALOME). The
NPA’s Mission Statement below exemplifies the group’s
ethics and concerns:
NPA mission statement
We are a unique group of former NAOMI research par-
ticipants dedicated to:
 Support for each other
 Advocacy
 Educating peers and the public
 Personal and political empowerment
 Advising future studies (heroin and other drugs) and
permanent programs
 Improvements in consent and ethics
 The right to a stable life and to improvement in
quality of life
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The goal of NPA is to have alternative and permanent
public treatments and programs, including heroin-
assisted treatment (HAT).a
NAOMI Patients Association study
In May 2011 the NPA decided to undertake their own
research about their experiences as NAOMI research
participants. They were particularly interested in record-
ing their experiences during and following NAOMI and
making recommendations for other heroin and drug
substitution research experiments and programs. They
met with co-author, Susan Boyd, in the spring of 2011
and decided to work together to conduct qualitative re-
search: focus groups, individual interviews, brainstorm-
ing sessions, and writing workshops with NPA members.
NPA members also wished to write a report about their
experiences. This paper draws on the brainstorming ses-
sion and focus groups that were conducted from April
to June in 2011 [1], and events following the research.
The NPA research project received ethics approval
from the University of Victoria, B.C (Protocol Number
11-052). All NPA participants were granted confidential-
ity and anonymity and signed a consent form prior to
participating in the focus groups. However, all NPA
members insisted that their first name be included on
their creative writing. At the brainstorming session 20
NPA members identified several topics they wanted to
discuss in later focus groups. The first focus group took
place in May 2011 and 10 NPA members (four women
and six men) discussed the topics identified in the
brainstorming session. The second focus group took
place in June 2011 and nine NPA members participated
(six men and three women).b Each focus group was
audiotaped and transcriptions were made. After careful
reading and coding of the transcripts, five primary
themes were identified:
 Beneficial outcomes of being a participant in NAOMI
 Problematic outcomes of being a participant in
NAOMI
 Ethics and Consent
 Creative writing/Everyday life
 Recommendations for other research projects and
programs
This paper highlights the experiences of the NPA
members in their own words. The themes identified
above, except for the creative writing, are expanded upon
in these pages. The findings presented in this paper pro-
vide a lens to understand how people addicted to nar-
cotics navigate their lives in and outside of the DTES and
how becoming a research subject for the NAOMI project
impacted their lives, both positive and negative. The first
section of the paper introduces readers to the DTES and
a number of ethical issues, including the impact of re-
search conducted in the area. This section is followed by
guidelines and principles created by VANDU for re-
searchers working in the DTES and elsewhere. The next
section provides a brief history of Canadian drug policy,
heroin-assisted treatment and the circumstances that led
to the NAOMI clinical trial. Following are quotations,
through which the NPA provides insight into the lives of
their members during the NAOMI clinical trial both
within and outside of their role as drug users and re-
search subjects. Finally, NPA members outline guidelines
for future drug substitution studies and programs, and
ongoing advocacy. This paper concludes with the hope
that future research and heroin treatment programs will
benefit from the experiences, reflection, and advocacy of
the NPA.
The downtown eastside, research, and ethics
NPA meetings take place at VANDU, on East Hastings
Street in the DTES. The NAOMI clinic was also lo-
cated in the DTES. Although it was not always so,
today the Downtown Eastside of Vancouver is Canada’s
poorest urban neighbourhood [2]. According to the city
of Vancouver, the DTES includes Gastown, Victory
Square, Strathcona, Chinatown, industrial lands, and
the Oppenheimer and Thornton Park areas. Just over
18,000 people live there [3] pp. 6,3. It is a racially di-
verse population of Aboriginals, Asians, Latinos/as and
Caucasians [3] p. 9. The DTES has a number of single-
room occupancy (SRO) establishments and a visible
street scene [3] p. 14. The street scene is directly re-
lated to cutbacks at the federal, provincial, and local
levels, leading to poverty and a lack of social housing
and private space. Gentrification of the area has also
made it more difficult for long-time residents to find
safe, permanent, and affordable housing. For women,
especially First Nations women, the DTES is also the
site of much violence, often linked to the sex trade, but
more generally, to everyday life [3] p. 25, [4-6]. The nega-
tive outcome of drug prohibition and the criminalization
of heroin, cocaine, and other drugs is played out on the
streets daily. Prohibition fuels an illegal market and, un-
like in more privileged neighbourhoods, drug use and
selling is more visible on the street in the DTES instead
of hidden behind closed doors. This situation makes
people more vulnerable to unwanted police attention
and prison time, and sometimes drug-related violence
[3] p. 24.
It is well documented that drug prohibition, a reliance
on the criminal law to eliminate illegal drug production,
selling, and use, has worsened the health and well-being
of drug users [7]. The results of prohibition include in-
creased imprisonment and the undermining of health
services, including prevention and treatment services
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that would more effectively counter HIV and Hepatitis C
epidemics and drug overdose deaths [7]. Effective coun-
termeasures are undermined. (For example, Insite, the
safe injection site in Vancouver, was challenged by the
federal government which actively sought to close it
down and challenged its legitimacy in court despite sci-
entific evidence demonstrating its effectiveness.) Prohib-
ition also fuels social and legal discrimination and
stigma, and the marginalization of people who consume
illegal drugs. Globally, law enforcement and civil initia-
tives over the last 100 years have led to increased incar-
ceration, prison building, and the infringement of human
rights [7]. Recently in Canada, the Conservative federal
government enacted mandatory minimum sentencing for
some drug offences. In March 2012, Bill C-10, the Safe
Streets and Communities Act, was enacted.
The individual and social costs of this Act could be
immense: families may be torn apart when parents are
sentenced to prison; children may be apprehended by
the state; and the loss of income for families may leave
many destitute. At the weekly meetings, the NPA see
daily that it is the poor and marginalized who suffer the
most under prohibition; they, not an imagined “drug
king pin,” are arrested, convicted, and sent to prison.
Yet, prohibition is not uncontested. In the 1990s activ-
ists in the DTES came together to challenge the status
quo and they continue to do so today.
The DTES gained national and worldwide attention in
1997 when a public health emergency was declared in
response to the growing rates of HIV, Hepatitis C, and
overdose deaths in the area. Stemming from those
events, community activists played a major role in a so-
cial movement for change in the DTES, demanding an
end to drug prohibition, more social supports, and the
establishment of more harm reduction services, such as
a safe injection site [8].
VANDU also emerged in 1997, the first drug user union
in Canada. VANDU has long advocated for their members
and for change in the DTES and to Canada’s drug laws and
policy [9]. Due to these efforts and those of other commu-
nity activists, the DTES has witnessed some changes since
1997. VANDU secured a permanent site and offers sup-
port, education, and advocacy for group members. Needle
exchange expanded, the Portland Hotel Society provided
more housing for people with addictions and/or mental
illness, the first safe injection site, Insite, opened its doors
in 2003, and a heroin prescription trial, NAOMI, opened
its doors in 2005. Yet, for many residents, especially
people who consume illegal drugs such as heroin and
crack, the social conditions of their lives barely changed.
Lack of affordable and safe housing, poverty, racial profil-
ing, criminalization, violence, drug prohibition, and dis-
crimination continue to shape the lives of people living
in the DTES [3].
At the same time that activists in the DTES have
striven to improve the conditions of people’s lives in the
area and to advocate for change, health and social sci-
ence researchers began to conduct studies in this area
and many of the residents became research subjects
[6,10-16]. Many of these studies made clear empirically
what the residents already knew: a myriad of health and
social factors detrimentally shape the lives of people in
the DTES.
NPA members wanted to conduct their own research,
in part because they had participated as research sub-
jects in the NAOMI trial. However, for many NPA mem-
bers, the NAOMI trial was not the first study in which
they had participated. In the DTES of Vancouver, one of
the only ways to access services or to make ends meet is
to become a research subject. Research honorariums,
bus passes, stipends, and for a short period, access to
unadulterated legal heroin, are now familiar exchanges
in the DTES.
In 2005, the Canadian HIV/AIDS Legal Network pub-
lished, “Nothing About Us Without Us” – Greater, Mean-
ingful Involvement of People Who Use Illegal Drugs: A
Public Health, Ethical, and Human Rights Imperative
[17]. This booklet responded to the negative impact of
programs and research studies on people who use illegal
drugs, including the participants’ exclusion from the de-
velopment of studies, programs, and services. This book-
let includes a manifesto by people who use illegal drugs:
the authors recommend greater involvement of people
who use drugs in the programs and services that affect
their lives, as well as in broader policy and advocacy
work on HIV/AIDS and Hepatitis C. A recent 2011 re-
port by the World Health Organization and UNAIDS,
Ethical engagement of people who inject drugs in HIV pre-
vention trials, echoes the recommendations by Canadian
HIV/AIDs Legal Network. They also recommend that re-
search populations “participate in a meaningful way in
each stage of a trial, including the earliest stages during
which a study is conceptualized and research protocols
are developed” [18], p. 7. In addition they recommend
that all research subjects continue receiving treatment at
the end of a trial if the care and treatment are effective
[18], p. 26.
The issues surrounding research, ethics, and exploit-
ation have long interested drug user groups and activ-
ists because they have themselves become research
subjects or witnessed others participating in trials and
studies (further on we highlight Dan Small’s and Ernest
Drucker’s concerns about these issues in relation to
NAOMI). Dara Culhane, a researcher and long-time
resident in the DTES, also critiques the ethics of some of
the research conducted in the DTES. She is critical of
“data-mining,” which she defines as “researchers using
research subjects principally as means to researchers’
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ends” [19], p. 260. She argues data-mining has become a
“central dynamic in everyday encounters between re-
searchers and researched” in the DTES even though resi-
dents have strongly protested against these interventions
[19], p. 260. In the section below we draw extensively
from Dara Culhane’s recent 2011 article published in
Anthropologica [19].
Culhane notes that the DTES has become an “inter-
nationally renowned centre for medical and pharmaceut-
ical research on HIV/AIDS and addiction” dating back
to the public health crises in 1997 [19], p. 261. She ex-
plains that along with harm reduction services came
clinical trials (including NAOMI) and studies to prove
their effectiveness and thus, “a research industry ex-
panded dramatically” in the DTES [19], p. 261. Yet the
social conditions of people’s lives there have for the most
part worsened.
Culhane questions the role of many marginalized
people in the DTES “to serve as research subjects” in
varied social science studies, clinical trials, and art pro-
jects. She argues that for marginalized people, “access to
public support and private philanthropy increasingly de-
mands performing” and telling one’s story in exchange
for “food, housing, health care, attention, affection, com-
passion and belonging.” Researchers, of course, benefit
from “grants, publications, tenure and promotion” [19],
p. 262. Culhane writes that the stories told are true and
the pain they reveal is real. Many DTES researchers try
hard to be ethical; however, the conditions of poverty
and exploitation in which studies take place challenge
researchers to find ways to support research subjects'
autonomy and self-determination within projects them-
selves and within society as a whole.
Because people living in the DTES need income and
services, these needs shape how their stories are told to
researchers. Responding to these events in the DTES,
the NPA decided to conduct their own research, to tell
their own stories, in their own words. They adopted the
principles of collaborative research and “Nothing About
Us Without Us” [17]. These research perspectives offered
an approach to make visible the experiences of the NPA
members. These perspectives also emphasize “research
for social change” and policy relevance [20]. During the
research process, the issues of participation, ethics, and
consent were discussed by the NPA. In these pages the
NPA asks their readers: how can there be consent to
participate in studies, to tell one’s story, including par-
ticipation in the NAOMI clinical trial, when the social
conditions of people’s lives are so compromised? How
can research be initiated and guided by the experiences
and knowledge of those most affected by drug prohib-
ition? The NPA members speak to these issues and
others in the following pages. In the fall of 2011,
VANDU, including members of the NPA, created further
guidelines and principles for researchers working with
VANDU and the NPA. They note that research is
conducted against the backdrop of the war on drugs:
 The drug war didn’t start because of a lack of
research or “bad” research and we don’t think it will
end because of “good” research. The active struggle
of people oppressed by drug war policies and
fighting for their liberation will be the decisive factor
in ending the drug war. Researchers can play a
positive role when they act as supporters, allies and
partners of this movement for liberation.
 Research is political. Research is shaped by funding,
by the career aspirations of researchers, by the
political tendencies of research institutions, by
government funding and intervention, by peer
pressure and by class, racial and gender biases.
 The relationship between the researcher and the
researched is not in and of itself empowering or
liberating. It only becomes so when organized
movements of the oppressed group play an active
role in shaping and carrying out the research.
 Researchers should leave the organizations of
oppressed people that they work with stronger than
when they came in; if they don’t, they are part of the
problem and not part of the solution [21].
The NPA adopted the words below to further guide
their own research. They are written by long-time DTES
activist, historian, and poet Sandy Cameron, and are an
excerpt from his poem, Telling Stories.
Telling Stories
We need to tell our own stories.
If we don't tell our stories,
people with power
will tell our stories for us [22].
It is from this place that the NPA began their own re-
search, to tell their own story in their own words. This
paper also provides a brief history of Canadian drug policy
and heroin-assisted treatment in order to contextualize the
NPA’s experience.
Canadian drug policy and heroin-assisted
treatment
All of the NPA members were research subjects in the
NAOMI clinical trial in Vancouver, B.C. The following
section outlines briefly the history of drug policy in
Canada, drug maintenance therapy, and the circum-
stances that led up to the NAOMI trial, followed by a
summary of the research findings of the NAOMI trial.
Prior to the criminalization of narcotics in Canada in
the early 1900s, opiate (and opiate derivatives) use was
acceptable in society to treat a wide range of illnesses
[23-25].c In the 1700s and 1800s, settlers to Canada
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brought opium remedies, patent medicines, and elixirs
to treat illness. Most settlers could not afford the ser-
vices of a doctor; nor were doctors available in rural
areas, which made up most of Canada then. Although
Aboriginal healers had their own array of remedies, the
practices of colonization led white settlers to eventually
reject Aboriginal medicines and to use drugs with which
they were already familiar, including a wide array of oral
patent medicines that were made available at stores and
through mail order at Eaton’s and Sears, Roebuck and
Company [26]. Doctors heralded these drugs (opium, co-
caine, and marijuana) in liquid form for their healing
properties to control coughing, address gastro com-
plaints, and treat severe pain. Opiates were advertised to
appeal to women as caregivers to their families. In
Canada, Britain, and the U.S., it was quite common for
households to contain patent medicines and remedies
that included opiates. In fact, prior to the criminalization
of opium and heroin, the typical persons using opium or
its derivatives, such as Laudanum, were law-abiding
middle and upper class white women [23,24,26,27].
However, what was once considered a personal matter
shifted in the late 1800s and early 1900s. In 1803, mor-
phine was isolated from opium. This was the first time
in history that a chemical compound was extracted from
a plant. This event led to other scientists and pharma-
cists experimenting with an array of plant compounds,
and eventually to the creation of synthetic drugs and our
modern day pharmaceutical and chemical industry [28].
Heroin is a derivative of morphine. It is more potent than
morphine in that it produces the same effect but with
smaller doses. Heroin was marketed by Bayer Pharmaceut-
ical Products in 1898. Early on, it was popular as a cough
suppressant; its popularity and medical applications were
illustrated by the advertisements for its use that appeared
in medical journals in the early 1900s [25].
For the purpose of this paper, we only wish to point out
that opiates and opiate derivatives were in common use in
Canada prior to Canada’s first narcotic legislation, the
Opium Act of 1908 and the Opium and Narcotic Act of
1911. The Opium Act was not enacted because of evidence
that opiates caused physiological harm; rather it was
enacted to control Chinese Canadians in western Canada,
and its original focus was on the sale and manufacture of
smoking opium and not the array of liquid-based opiate
drugs that white settlers consumed [29]. From their incep-
tion, Canada’s drug laws have been racist, class-based, and
gendered in their formation and application. It was as-
sumed that the Opium and Narcotic Act, for example,
would not be applied to white middle-class citizens [29].
The Act was passed and subsequent amendments crimi-
nalized other drugs. As the schedule of prohibited drugs
expanded, so did penalties and police/RCMP budgets over
the years. The most prominent feature of Canada's drug
policy over the last century has been a reliance on the
criminal law, also called “prohibition” [30]. These laws
were enforced by the RCMP and other police forces in
Canada. Police and RCMP also became key initiators of
harsh drug policies [31,32].
Following the criminalization of opium, heroin, and a
number of other drugs in the early 1900s, a new group of
citizens became criminals and they had few options for
obtaining legal and illegal narcotics. Unlike doctors in
the U.K., Canadian doctors did not retain the right to
prescribe narcotics for maintenance purposes and no
publicly funded drug maintenance programs were set up.
In the 1920s, the police focused on arresting and deporting
Chinese Canadian residents convicted of possessing opium
in smoking form and closing down opium dens. Eventually
police attention shifted to white narcotic users, especially
those who were poor and working class. As the opium
dens closed, narcotic users switched to other drugs such as
heroin bought on the illegal market. Prison time was often
their fate as Canada’s drug laws became more and more
harsh. In the 1940s the RCMP coined the phrase “criminal
addict” to describe people addicted to illegal drugs. They
wanted to make clear that first and foremost, these people
were criminals; the RCMP promoted the idea that addic-
tion was secondary and stemmed from having a “criminal
lifestyle.” The RCMP were vehemently opposed to drug
maintenance therapy. Abstinence and prison time were
touted as the solution to addiction to narcotics. Halliday,
an addiction specialist at the time, asserts that in Canada
prior to the 1960s, the “absence of community treatment
facilities must be directly related to the social concept of
the addict as criminal first, and a sick person second” [33],
p. 413. By the 1950s medical doctors gained new ground
and psychiatric treatment in prison emerged as one re-
sponse for new narcotic users [31,32,34].
Another perspective began to emerge in Canada in the
1950s, a drug treatment movement centred in Vancouver,
B.C. Doctors, social workers, politicians, and concerned
citizens rallied for change, including the setting up of drug
maintenance programs for people addicted to narcotics
[32,35]. Although they were not completely successful at
that time, a number of small programs were later set up in
Canada. These programs included limited methadone
maintenance programs and some drug treatment pro-
grams in prisons, such as Matsqui prison in B.C. It was
not until the 1960s and early 1970s that publicly funded
methadone maintenance programs and drug treatment
programs and other services became available throughout
Canada, and even then rural areas did not have services
and services in urban areas were quite restrictive [32,33].
Narcotic users have long questioned why heroin is illegal
and why it is not offered as a choice for drug maintenance.
From the 1960s on, methadone became the standard treat-
ment in Canada for people addicted to narcotics and this
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treatment was expanded in B.C. in the late 1990s. Yet right
from its inception, it was clear that methadone mainten-
ance does not work for everyone. Research and later drug
user groups made it clear that many narcotic users do not
benefit from methadone therapy and many participants
drop out or are kicked out of treatment for not complying
with rigid regulations. Rather than methadone mainten-
ance, people who participated in these programs requested
heroin. But their requests fell on deaf ears.
However, heroin prescription is not unusual: the U.K.
has long had heroin prescription as part of its addiction
treatment services, and in the U.S., a number of heroin/
morphine clinics were opened following prohibition.
These public clinics were eventually closed down as the
U.S. moved towards a more prohibitionist and criminal
law model of drug policy and, at that time, little else was
put into place to help people addicted to narcotics other
than prison programs such as Lexington [36].
In the early 1950s, the Senate Special Committee on
the Traffic in Narcotic Drugs in Canada visited Oakalla
prison farm in Burnaby, B.C. This committee noted in
its report that “without exception” all of the former
narcotic users in the prison group advocated for the
“legalized provision of drugs” [37], p. 344. The report
also pointed out how medical and professional “addicts”
were treated differently in Canada. From 1928 to the
early 1970s, the Division of Narcotic Control (within
the Federal Department of Health) kept a registry and
case files on every known illegal drug user in Canada,
whom they referred to as “criminal addicts.” Each file
contained police reports, photos, criminal records, and
memos and letters from doctors, prosecutors, and par-
ole boards. Every arrest for narcotic possession or traf-
ficking was noted in the files. The police also included
notes from drug trials to inform the RCMP and special
prosecutors about testimony and trial outcomes. When-
ever the department found out that a known drug user
was obtaining drugs from a doctor, they set out to in-
vestigate. A separate filing system was kept for medical
professionals (doctors, nurses, pharmacists) known to
use narcotics; yet to date, these files are unavailable and
no researcher has been able to access them [31]. Most
significant for the purposes of this paper, the two cat-
egories of narcotic user were treated differently: prison
time was handed out to those labelled criminal addicts,
and at the same time, medical professionals received
private treatment and cautions.
There is a long history of advocating for people who
use criminalized drugs, including legalizing narcotics in
Canada and setting up alternative drug maintenance pro-
grams, such as heroin therapy. In the 1990s, Switzerland
implemented heroin-assisted treatment (HAT) in several
cities. The success of the Swiss program led to many other
countries adopting similar models, including Germany, the
Netherlands, Spain, Belgium, and Denmark. There is now
a “rich data set on the feasibility, efficacy, safety and ef-
fectiveness of HAT” [38]. As noted above, heroin has not
been available in Canada for maintenance purposes. In
1998, the first North American Opiate Medication Initia-
tive (NAOMI) Working Group was formed to conduct a
HAT trial in the U.S. and Canada. Because it was not pos-
sible to get a U.S. site for the trial, Canadian investigators
applied for a 3-site study in Canada. Funding approval was
granted by the Canadian Institutes of Health Research
(CIHR) in 2002 followed by approval from the Regulatory
Branch of Health Canada in 2003 [39]. NAOMI eventually
opened its doors in only Vancouver and Montreal.
NAOMI
In 2005 posters went up on telephone poles and walls
throughout the DTES of Vancouver, with a telephone
number to contact the NAOMI research people. NAOMI
was a clinical trial that tested whether heroin-assisted ther-
apy benefits people suffering from chronic opiate addic-
tions who have not benefited from other treatments. The
target population for NAOMI included men and women
over the age of 25 who were “chronic, opioid dependent,
daily IDUs” and who had previously been unsuccessful
with methadone maintenance and other treatment modal-
ities. Participants in the NAOMI study were randomized
into one of two groups: one received injections of heroin
or Dilaudid (hydromorphone), and the other received oral
methadone. The NAOMI study provided heroin/Dilaudid
for 12 months, followed by a 3-month transition period.
When they entered the study, participants were not cur-
rently on methadone maintenance therapy (MMT) and
had to be off MMT for at least six months prior to partici-
pating in NAOMI. Apparently this criteria for entering the
study was added after response from Canadian health au-
thorities and MMT providers who were worried that their
patients would drop out in order to participate in NAOMI
[39]. This is the opposite of participant criteria in other
countries that actively recruited MMT patients. In fact the
criteria of these other trials made clear the participants
“must” currently be on MMT. The NAOMI trial began en-
rolling people in February 2005 in Vancouver, B.C. Recruit-
ment ended in April 2007 and the last participants left the
program in 2008.
NAOMI study results
1. Heroin-assisted therapy proved to be a safe and
highly effective treatment for people with chronic,
“treatment-refractory” heroin addiction. Marked
improvements were observed including decreased
use of illicit “street” heroin, decreased criminal
activity, decreased money spent on drugs, and
improved physical and psychological health.
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2. The NAOMI trial attracted the most chronic and
marginalized heroin users who were outside the
treatment system and continued to use heroin
despite numerous previous treatment attempts. Both
heroin-assisted therapy and optimized methadone
maintenance treatment achieved high retention rates
and remarkable response rates in this difficult-to-
treat group.
3. Contrary to pre-existing concerns, the treatment
clinics appeared to have no negative impacts on the
surrounding neighbourhoods.
4. Participants on hydromorphone [Dilaudid] did not
distinguish this drug from heroin. Moreover,
hydromorphone appeared to be equally effective as
heroin although the study was not designed to test
this conclusively [40].
After a year of receiving heroin (or hydromorphone),
participants entered a 3-month transition period. Dur-
ing this period, all NAOMI participants were offered a
range of traditional treatments, including methadone
maintenance and detox. After the 3-month transitional
period, the research participants were no longer part of
the study and no further treatment or supports were of-
fered, although follow-up interviews were conducted 18
and 24 months following participants’ entrance into
the study (thus, interviews occurred 3 months and 9
months after exiting the study). However, 16 percent
of the total heroin/hydromorphone participants did
not participate in the final follow-up interviews; thus it
is difficult to assess the NAOMI researchers’ claims
about participants’ medical status, treatment retention,
drug use, legal situation, quality of life, etc. following
cessation of treatment [41]. What is indisputable is that
the NAOMI findings demonstrated that heroin-assisted
therapy was an effective treatment that improved phys-
ical and psychological health when the participants
were receiving treatment [39,41].
As early as 2006, Dan Small and Ernest Drucker
questioned why both Canadian federal and provincial
policy makers ignored the plethora of scientific evidence
throughout the world that already demonstrated the effi-
cacy of heroin prescription. They noted that the federal
government of Canada rejected an early 2001 request by
the Portland Hotel Society (PHS), a non-profit “social,
health, and housing agency” in the Downtown Eastside, for
legal permission to prescribe heroin in Vancouver, B.C.
[42] Although they praise the NAOMI researchers for their
efforts to provide heroin prescription in Canada, they also
make clear that the NAOMI trial was problematic on
many fronts, including the absence of an ethical exit strat-
egy, the lack of informed consent without duress, and the
failure to provide a permanent program [42], p. 11. They
also point to the internationally accepted ethical standards
for research outlined in the Declaration of Helsinki. The
Declaration states: “At the conclusion of the study, every
patient entered into the study should be assured of access
to the best proven prophylactic, diagnostic and therapeutic
methods identified by the study” [43]. An adequate exit
strategy should have been included in the research pro-
posal to transfer patients to a permanent program at the
end of the NAOMI trial if the study results were positive
(which they were). At the very least, HAT on compassion-
ate grounds should have been provided for. Dan Small and
Ernest Drucker assert that heroin prescription has im-
proved the health and quality of life for participants around
the world. They conclude that if the “research in another
sector were as clear, this treatment protocol would by now
be available” [42], p. 12.
The NPA participants also questioned why they were de-
nied HAT and why such a successful trial would close
down. Outside Canada, heroin-assisted therapy is offered
in a number of countries and none of these programs shut
down following their study stage; due to the fact that study
results were positive, these programs continued on a per-
manent basis and/or participants were granted further
HAT on compassionate grounds. For an excellent sum-
mary of HAT programs, see [44]. The Netherlands HAT
randomized trial conducted over four years demonstrates
that the longer a patient is offered HAT, the better is the
chance of continued good health (in contrast to those pa-
tients with only one year of HAT) [38]. Continuation of
HAT is thus essential. The Canadian NAOMI project is
the only heroin-assisted study that failed to continue
offering HAT to its participants when the study ended
in Vancouver [44].d In 2007, Health Canada refused com-
passionate use of heroin for NAOMI participants; however,
Health Canada left the door open for the NAOMI re-
searchers to continue providing heroin through their study.
Yet, they failed to do so.
NAOMI from the Perspective of the NPA
The preceding sections outlined some of the findings of
the NAOMI trial from the perspectives of researchers
involved in that study. This section of the paper is drawn
from what the research participants said about their ex-
perience in the NPA focus groups about NAOMI. It
highlights the experiences of the NPA members when
they were NAOMI research subjects.
NPA members discussed why they chose to become
NAOMI research subjects. Two members expressed
their views:
Well, we all wanted heroin. Everybody wanted the
heroin. (female NPA participant)
That’s why we went through it all. (male NPA
participant)
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Participants expressed why they were interested in
participating in the NAOMI clinical trial. The trial of-
fered something that participants wished to obtain: her-
oin, a drug currently criminalized in Canada.
NPA members also discussed the physical space of the
NAOMI clinic over the study period. Participants in the
study were expected to arrive at the clinic on the corner
of Hastings and Abbott Streets three times a day (morn-
ing, afternoon, evening) with about four hours between
each dose. The people who received heroin came in the
entrance on Abbott St., and the people receiving metha-
done entered on Hastings St. The two groups remained
physically separate during the study. When the heroin
participants arrived, they had a 10-minute window for
their appointment. They were not allowed to arrive early
or to be late.
They didn’t want people lining up. (male NPA
participant)
Okay? Not 10 minutes and 10 seconds. You had 10
minutes . . . . The computer would not allow you to be
logged in if you were past that 10-minute window.
(female NPA participant)
Participants were buzzed though a double door that
had security cameras; the doors were continuously
locked. People then had to be buzzed through a sec-
ond door. Patients were then logged on to a computer
and they entered a waiting room for a 15-minute ob-
servation prior to injecting their dose of heroin or
Dilaudid. After being observed for 15 minutes, on a
first-come-first-served basis, participants were brought
into the injection area (similar to Insite) where a
nurse sat behind a glass partition and supplies were
handed to people in a tray, including a prepared syr-
inge that was scanned to match each participant’s
name. Then they had seven minutes to inject,
followed by a half-hour observation period following
their dose (3 × day). Participants sat in a lounge dur-
ing this observation period.
You were given seven minutes to inject your heroin.
(male NPA participant)
There were nurses and social workers observing
people, and a doctor was on site. Every two weeks the
participants met with the doctor to discuss their dose.
They could also arrange for a meeting in between these
appointment times.
The NAOMI participants spent a lot of time at the
clinic waiting for their medication and being observed
before and after their dose. In that time, they talked with
one another, formed friendships, and created activities to
fill in the time. One NPA member wrote about her time
waiting at NAOMI with other participants:
Supper at NAOMI
It’s 5pm, time to go to my regular evening medication
of heroin. All done with the medical part. Now to the
fun stuff. Dave brought a Maple Leaf roast pork and
gravy dish, fed about 8 people, the 4 at our table and
then as many as we can. I brought bread and salad.
So dinner tonight is:
“Hot Pork Sandwich – with gravy, Caesar Salad and
Vanilla pudding with Strawberries”
Supper’s over, I got fed and now it’s time to relax and
do our crosswords.
Bye! See you for breakfast. (Dianne, NPA member)
NPA members noted that by abiding by the protocols
and regulations set up by NAOMI for their attendance,
they spent a lot of their day at the clinic and it was difficult
to do anything outside the clinic. One NPA member said:
Well, you couldn’t do anything in between. (male NPA
participant)
NAOMI benefits
The NPA members spoke about the benefits they experi-
enced during their time as participants in the NAOMI
trial:
They helped me get a room at the Empress Hotel
and from there everything started to move forward.
I didn’t have to worry about having to get up every
morning and run all over hell’s half acre just like a
chicken with my head cut off wondering where I
was going to get the money to get better. (female
NPA participant)
And life improved, I suppose. It was kind of a blurry year
but all in all I think it was better. I don’t know. I was
happy, at least I think I was happy. You know, I wasn’t
miserable a lot. I wasn’t sick, you know, I wasn’t running
around trying to get $10 all the time. Yeah, so I mean it
was good. (male NPA participant)
I am glad I did go through it even if we did get dropped
because it was, it was the best years of my – couple of
years in my life. I really learned how to be myself without
having to be looking for money all the time. I learned
how to do normal things, and be a good president [at
VANDU] and stuff. (female NPA participant)
I was in a bubble for 15 months, but I mean, I hit
those doors at 72 pounds and, you know, here I am
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now and it’s not – NAOMI. I had a hell of a good
time. I was helped with housing. When I got an
abscess on my hip the nurses from NAOMI were
pulling up at Powell Place and coming and getting me
and driving me without me even asking them.
But it changed my life a lot. I wouldn’t regret doing it.
I’d do it again if they would offer it again. It was a
good thing for me while it lasted. It was great. It was
just good for me because I just can’t do methadone. It
is not an option for me. (male NPA participant)
It would give me a huge break in my life as an addict.
It would give me this huge, like, vacation, that was like
going to Florida, you know, and living on the beach
almost, you know, in terms of addiction. Going to
Florida. (male NPA participant)
The NPA members reveal that the benefits of the
NAOMI trial were deeply felt, as were the effects of not
having to hustle every day. However, some NPA mem-
bers were not able to comply with the requirements of
the NAOMI trial:
I was only on it for three months, but during the three
months my life got a lot better and when I did get
kicked off it my life was kind of screwed up because I’d
forgotten how to hustle to get, you know, to get things
happening. (male NPA participant)
Others observed that they were worried about what
would happen once the clinical trial ended:
We were being observed, the 15 minutes and a half
hour after, so there was a lot of talking going on and I
think one of the big subjects was, what are you going
to do when this was over? And I think that was, like,
probably the thing we talked about the most. (male
NPA participant)
I mean, once you finished talking about your daily
activities or whatever was going on in your life it
came down to, like especially as it got closer to the
end road. I think that it was helped by the fact
that it was staggered, the intake, so we would
always have somebody that was leaving. . .so we
had an idea it was coming all the time. . .(male
NPA participant)
NPA members expressed their concerns about the end
of the NAOMI clinical trial. One woman noted:
I just – you know, I cried like a baby the last day I
was there. (female NPA participant)
The lack of an adequate exit strategy for the patients
was sorely felt and is discussed more fully in the next
section.
Consent and expectations: what is consent under
drug prohibition?
All of the NPA participants signed consent forms to par-
ticipate in the NAOMI study. These forms were updated
from time to time. The NPA members discussed issues
of consent, ethics, and their expectations of the NAOMI
trial. They also felt optimistic that the study would even-
tually become a permanent program.
I went there with the full understanding it was a
study. It was a study. (female NPA participant)
The staff and the doctors were telling us no [the study
would not continue], but they never completely
extinguished that little dream that we had. . . . We
were optimistic. (male NPA participant)
I was given the impression that it would continue and
then the studies that had happened in Europe that all –
they’d all been on compassionate ground, so I really
thought it was going [to continue] . . .It really kind of
threw me for a loop when it didn’t happen that way.
(male NPA participant)
I knew it was a study and like everybody else it was going
to help the future generation. But for me it was a double-
edged sword . . . . I think the thing that’s flawed in this, in
the ethics, was the ethics approval, like, for them to
approve this study without fully – I mean, without
having an exit strategy in place that was doable.
There’s been these kind of studies done in other
countries before us. So they had a good idea of what
the results were going to be . . . And to go into that
without having a way out that worked for the client
or the participant, I think that was the -- that’s the
thing that wasn’t right, in my opinion. (female NPA
participant)
Several of the NPA members explained how consent is
problematic when researchers control the very drug that
is an integral part of their lives:
Our life depends on this drug and here we’re
offered this drug. Well, okay, so, I mean, I always
said, well, I would sign anything at that point.
(male NPA participant)
The NPA members also wondered why the positive
NAOMI trial findings were not fully considered by the
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federal and provincial governments. They wondered if
the failure to create a permanent program had to do
with their marginalized status as illegal drug users. The
NPA members noted that if a diabetes or cancer treat-
ment proved to be efficacious during a clinical trial, pre-
sumably the patients would continue to receive the
medicine or treatment.
If they give you a drug for – they’re experimenting
with a drug for cancer and it starts working. I mean,
what are they – what are you going to do? Oh, no.
You can’t have it anymore, we’re going to back off
here. (male NPA participant)
In contrast, the NAOMI patients were denied heroin-
assisted treatment when the trial ended.
The NPA members also noted that providing legal ac-
cess to heroin or any drug improves the lives of the user.
However, that in itself is not enough:
If you just give me the drug all the time are you
improving my life? Well, you’re improving my life as
far as the drug goes. You’re probably taking a lot of
the stress out of my life, but are you actually doing
these other steps? (male NPA participant)
The NPA members discussed how Canadian studies
rarely provide necessary social and economic supports
or lead to social change. Nor does drug policy necessar-
ily change as a result of these studies. However as the
following NPA participant notes, providing HAT along
with social and economic supports opens up more posi-
tive possibilities:
And then we could move forward in our lives. (female
NPA participant)
NPA recommendations for future “experimental”
drug maintenance programs
Drawing from the experiences of NPA members at
weekly meetings, the brainstorming session, and focus
groups, the NPA also developed recommendations for
future experimental drug maintenance studies and pro-
grams. They are as follows:
When experimental drug maintenance programs are
over, clients (research subjects), for compassionate rea-
sons, should receive the drug they were on as long as
they need it.
An ideal study would provide an umbrella of support
and services:
 Housing (most important)
 Access to medical treatment all under one roof
(nurses, family doctors, dentists, etc.)
 Access to welfare workers (who are familiar with the
area and the people who live there) and Ministry
representatives
 Access to nutritious food for self and family
 Support to move life forward (school, trade, family
unification)
 Access to lawyers
 Education/advocacy skills and access to advocates
 Diverse routes of administration available—oral,
smoking form, injection. Not all people want to
inject their drug.
An ideal study would utilize the time clients (research
subjects) spent on site, three times a day. This consider-
able amount of time could be used to support, educate,
and advocate. All future studies and programs should in-
clude an adequate exit strategy, and NPA and other her-
oin users should be part of the team from the beginning.
Following NAOMI: snapshot of the NPA, where
they were in 2011
Dave Murray, the founder of NPA, gathered the follow-
ing information on housing on June 11, 2011. Out of the
13 people present at the NPA meeting that day:
 seven lived in SROs (single room occupancy)
 two lived in social housing (specifically Woodward’s
social housing)
 four self identified as homeless (no fixed address)
Most of NAOMI participants (IDU side) were housed
in SROs during the study period. No official effort was
made by the study to assist them to get better housing
during or after the research project. Everyone present at
the Saturday NPA meeting said that they would have
liked help (B.C. Housing, etc.) to improve their living
conditions during the study (and today). The two people
living in Woodward’s (social housing) today were in
SROs during the study.
NPA member and friend Robert Vincent passed away
in late December 2011. His thoughts and writing are in-
cluded in the 2012 Report. In the Report, the NPA also
honoured the memory of other former NAOMI partici-
pants who have passed away [1]. The NPA continue to
meet every Saturday at VANDU and they continue to
offer support and advocacy to their members. They are
also active in trying to change drug policy, especially in
relation to HAT.
HAT in Vancouver
In December 2011, the SALOME (Study to Assess
Longer-term Opiate Medication Effectiveness) study
opened its doors in Vancouver. SALOME is another
clinical trial. Their website describes the study as testing
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whether hydromorphone (Dilaudid), “a licensed medica-
tion, is as good as diacetylmorphine, the active ingredi-
ent of heroin, at benefiting people suffering from
chronic opioid addiction who are not benefiting suffi-
ciently from other treatments. This study will also test if
those effectively treated with these two injectable medi-
cations can be successfully switched and retained to the
oral formulations of the medications” [45].
In order to test their hypothesis, the SALOME study
will compare the effectiveness of six months of inject-
able heroin with six months of injectable Dilaudid and
the effects of switching from injectable to oral heroin
or Dilaudid. However, NPA members question why the
SALOME trial will compare Dilaudid to heroin given
that HAT is already proven to be feasible, safe, and ef-
fective [38]. SALOME began active recruitment in
Vancouver, B.C. in December 2011. Utilizing a lottery
system, people who registered for the trial and were
deemed eligible were contacted. Participants will be in
the study for one year, followed by a 1-month transition
period where participants will be encouraged to partici-
pate, once again, in conventional treatments such as
methadone maintenance, drug-free treatments, and de-
tox programs (treatments that have proven to be ineffect-
ive for these participants). The repeated failure of
treatment efforts for participants is in fact part of the cri-
teria for selection of participants in SALOME, as was the
case in NAOMI.
In 2011 and 2012 the NPA met with SALOME re-
searchers prior to their recruitment of research subjects
and provided valuable input from their experiences as
NAOMI patients. They also shared with SALOME re-
searchers their recommendations for future HAT trials
and programs as outlined above. NPA findings were
also communicated at public events at Simon Fraser
University Woodward’s in November 2011 and VANDU
in February 2012, in Vancouver, B.C. However, in the
end, the SALOME researchers failed to put into place
the most significant recommendations of the NPA
outlined in this paper. In the pursuit of scientific evi-
dence, important issues and recommendations by the
NPA about consent, ethics, an adequate exit strategy,
and human rights have mostly been ignored. It must be
noted that the SALOME study also has no exit strategy
in place for its participants [45]. Thus, history may re-
peat itself in Canada.
NPA members assert that both the NAOMI and
SALOME clinical trials should have included an exit
strategy contingent on the efficacy of HAT, especially
given that international research on HAT supported
such an outcome. In other words, both studies should
have offered a provision for continuing treatment (if
they showed beneficence) for the participants. Contin-
ued treatment should have been built into the research
protocols. Instead, at the end of the 12-month period,
NAOMI participants had 3 months (and SALOME pro-
vides one month) to transition to other available conven-
tional treatments, such as abstinence based programs
and methadone maintenance treatment. Yet, as noted
earlier, failure to benefit from traditional treatments was
one of the criteria for participation in NAOMI, and now
SALOME. The NPA argues that adequate exit strategies
should have been built into the clinical trial and that
withholding treatment that proved effective for patients
is unethical. Furthermore the NPA members question
the responsibility healthcare investigators have to their
subjects in these studies; are they not “patients” rather
than merely “subjects”?
In response to questions raised by NPA about the
failure to provide an adequate exit strategy and provi-
sions for a permanent HAT program, both NAOMI
and SALOME researchers have recently pointed to the
complexities of the application process for HAT clinical
trials in Canada, communications and restrictions im-
posed by Health Canada, site-specific security concerns,
and funding. The researchers also note that they did re-
ceive ethics approval for their trials to proceed [41].
Yet, none of their explanations address the lack of an
adequate exit plan, nor do they fully explain their failure
to continue HAT for their patients. Nor do their explana-
tions address the ethical issues discussed by NPA mem-
bers in this article.
In this paper, NPA members express the benefits and
problematics they experienced during their time as par-
ticipants in the groundbreaking NAOMI trial. Also, con-
sent is contextualized. Consent is not only about ability
or mental competency to provide consent. The NPA
members made clear in the focus groups that they gave
consent to participate in the NAOMI study. However,
the NPA points to other ethical issues related to consent
that are not addressed by the NAOMI researchers. The
NPA illuminates how consent is compromised when
participants are vulnerable and marginalized, and essen-
tial social and economic supports are lacking for pa-
tients. They ask readers to consider some of the social
conditions that shape their live in the DTES: economic
marginalization, poverty, discrimination, violence, police
profiling, lack of housing, drug prohibition and the
criminalization of heroin, and inflated black market
prices for their drug of choice. As one NPA member
stated earlier: Our life depends on this drug and here
we’re offered this drug. . . . I always said, well, I would
sign anything at that point. He continues: I would prob-
ably say which finger do you want, you know, or which
arm do you want, you know.
Furthermore, the NPA members noted that if a can-
cer drug proved to be efficacious during a clinical
trial, would the patients be denied the drug at the end
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of the trial? The NPA members question why it is eth-
ical to deny NAOMI and SALOME patients the best
medicine — HAT. The NPA contends that the NAOMI
researchers should have pushed policy makers harder to
allow for on-going clinical prescription. They also assert
that SALOME researchers and Providence Health Care
should do the same now. As noted earlier in this paper,
Canada is the only country that did not continue to pro-
vide HAT to its patients following NAOMI.
Hoping to avert the same outcome with the SALOME
trial and any other proposed HAT trials, the NPA with the
British Columbia Association of People on Methadone
(BCAPOM) consulted with Pivot Legal Society, a non-
profit located in the DTES of Vancouver, B.C., whose
“mandate is to use the law to address the root causes of
poverty and social exclusion” [46]. They are working
closely with Pivot to create a different outcome, to assure
that the SALOME trial immediately becomes a permanent
heroin treatment program. Pivot asserts that should the
federal government erect a barrier to the recommended
shift to a heroin prescription program, the recent decision
of the Supreme Court of Canada in the Insite (Vancouver’s
safe injection site) case “supports the argument that the
federal government cannot deny a legal exemption to the
Controlled Drugs and Substances Act for patient health
care outside of a research setting when evidence demon-
strates the efficacy of such treatment. To do otherwise
would breach the Charter rights of patients needing med-
ical care” [47].
Conclusion
The NPA started a small revolution in Vancouver, B.C. It
is too soon to know the full outcome of their advocacy;
however, the NPA hopes that this paper and their earlier
Report [1] will guide future research studies and the set-
ting up of permanent heroin maintenance programs in
Canada and elsewhere. This paper provides insights into
the lives of the people who became research subjects
when they participated in the NAOMI clinical trial. The
NPA members advocate for the end of drug prohibition
so that other people will not be subject to the social and
legal discrimination that they face daily. Nor will people
feel compelled to participate in research projects in
order to have essential goods, drugs, services, and sup-
ports provided to them. The NPA encourages other
groups to engage in creating their own research to tell
their own stories to improve the lives of those most af-
fected by drug prohibition and to guide future programs
that offer supports and substitution drugs to users.
Endnotes
a In the fall of 2012 the NPA informally changed its
name to the SALOME/ NAOMI Association of Patients
(SNAP), to better reflect their current membership. A
number of NPA members are currently participating in
SALOME, a clinical trial in the DTES. However, for the
purposes of this paper, the authors refer to NPA because
it was in use during the initial NPA research period.
b The writing workshop took place on June 11, 2011
and 14 NPA members attended. Thirteen people con-
tributed writing pieces (5 women and 8 men).
c Opium is made from the opium poppy. It is one of
the oldest drugs recorded, the parent of all other nar-
cotics. It was an important item of commerce and used
widely for medical purposes.
dIn addition, the SALOME website states that: “Canada
will be the only country that has ever terminated the treat-
ment after showing success. The Canadian study team
applies for research funding to continue investigating ef-
fectiveness of licensed injectable opioids (the SALOME
trial).” Timeline: From Opium to Salome. [http://www.
providencehealthcare.org/salome/timeline.html]
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